Indications

Pradaxa® (dabigatran etexilate) (150mg and 110mg hard capsules) is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension. AF, atrial fibrillation; NYHA, New York Heart Association.

Praxbind® (idarucizumab) is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required:

  • For emergency surgery/urgent procedures
  • In life-threatening or uncontrolled bleeding

Jardiance® (empagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

  • As monotherapy when metformin is considered inappropriate due to intolerance
  • In addition to other medicinal products for the treatment of diabetes.
For more information or to access the current prescriber guide and Summary of Product Characteristics, please visit www.medicines.org.uk/emc (GB) or www.emcmedicines.com/en-GB/northernireland/ (NI)

This resource has been developed, organised and funded soley by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company and the speaker prior to broadcast. Editorial support for this video has been provided by OmniaMed Communications.

On-demand video

The modern management of non-valvular atrial fibrillation in patients with multimorbidity

This promotional video presentation was originally broadcast on 4th May 2022.

Please note that the speaker(s) are not able to answer questions from attendees watching the video on-demand.

Indications
Pradaxa® (150mg and 110mg hard capsules) is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension.a,b AF, atrial fibrillation; NYHA, New York Heart Association.

Praxbind is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: • For emergency surgery/urgent procedures • In life-threatening or uncontrolled bleeding.

Resources

Pradaxa® [dabigatran etexilate] patient support booklet

This resource has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company prior to the symposium. Editorial support for this symposium has been provided by OmniaMed Communications.

Pradaxa® [dabigatran etexilate] patient starter card

This resource has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company prior to the symposium. Editorial support for this symposium has been provided by OmniaMed Communications.

Preventing AF-related stroke – A patient discussion guide

This resource has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company prior to the symposium. Editorial support for this symposium has been provided by OmniaMed Communications.

Company profile

We are Boehringer Ingelheim.
Family-owned. Purpose-led. Innovation-driven: We work to improve health for people and animals.

Aspiring to make new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Established in 1885, we have always been independent and family-owned, meaning we have the freedom to pursue our purpose –
identifying health challenges of the future, and targeting areas of need where we can do the most good.
By working collaboratively, we aim to accelerate the delivery of medical breakthroughs to help transform the lives of patients now, and for generations to come. In the UK we do this through scientific innovation – taking on the biggest challenges in medicine. We invest in sustainable healthcare – planning for the long term alongside the NHS and our partners in the veterinary world. We support digital transformation by partnering with innovators to drive healthcare improvements.

We are committed to tackling the challenge of climate change. We serve local and global communities through our social impact programme and we support social entrepreneurs who find healthcare solutions for the most vulnerable.

More information can be found at www.boehringer-ingelheim.co.uk

PC-GB-106399 V1 | May 2022

PC-GB-106399 V2 | May 2022